Cargando…
Safety of Combined Targeted and Helixor(®) Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study
Background: Newer personalized medicines including targeted therapies such as PARP inhibitors and CDK 4/6 inhibitors have been shown to improve the survival of breast and gynaecological cancer patients. However, efficacy outcomes may be ham5pered by treatment discontinuation due to targeted therapy-...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916034/ https://www.ncbi.nlm.nih.gov/pubmed/36767928 http://dx.doi.org/10.3390/ijerph20032565 |